<DOC>
	<DOCNO>NCT00096304</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , epirubicin docetaxel , work different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : This phase I trial study side effect best dose epirubicin give docetaxel treat patient metastatic prostate cancer .</brief_summary>
	<brief_title>Epirubicin Docetaxel Treating Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose epirubicin administer docetaxel patient metastatic , androgen-independent adenocarcinoma prostate . - Determine response rate ( objective prostate-specific antigen response ) duration response patient treat regimen . OUTLINE : This dose-escalation study epirubicin . Patients receive epirubicin IV 30 minute docetaxel IV 1 hour day 1 8 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos epirubicin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow every 3 month 2 year . PROJECTED ACCRUAL : A total 3-36 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate Meets 1 follow criterion : Measurable disease prostatespecific antigen ( PSA ) value Unidimensionally measurable lesion ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan Histologic confirmation require measurable disease confine solitary lesion Nonmeasurable disease PSA ≥ 5 ng/mL* The following consider nonmeasurable disease : Bone lesion Pleural pericardial effusion Ascites CNS lesion Leptomeningeal disease Irradiated lesions unless disease progression document prior radiotherapy NOTE : *Patients PSA ≥ 5 ng/mL eligible Progressive systemic disease despite ≥ 1 prior standard endocrine therapy orchiectomy , luteinizing hormonereleasing hormone ( LHRH ) agonist , diethylstilbestrol , indicate 1 follow criterion : Objective evidence increase &gt; 20 % sum long diameter target lesion time maximal regression OR appearance 1 new lesion One new lesion bone scan secondary prostate cancer AND PSA ≥ 5 ng/mL Elevated PSA ( ≥ 5 ng/mL ) 2 consecutive increase baseline ( take ≥ 1 week apart ) Serum testosterone ≤ 50 ng/dL patient without bilateral orchiectomy Patients bilateral orchiectomy continue therapy primary testicular androgen suppression ( e.g. , LHRH analogues ) PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Meets 1 follow criterion : AST ALT normal AND alkaline phosphatase ≤ 5 time upper limit normal ( ULN ) AST ALT ≤ 1.5 time ULN AND alkaline phosphatase ≤ 2.5 time ULN AST ALT ≤ 5 time ULN AND alkaline phosphatase normal Bilirubin normal Renal Creatinine ≤ 1.5 time ULN Cardiovascular No uncontrolled high blood pressure No unstable angina No symptomatic congestive heart failure No myocardial infarction within past 6 month No serious uncontrolled cardiac arrhythmia No New York Heart Association class III IV heart disease Other Fertile patient must use effective contraception least 3 month study participation No peripheral neuropathy ≥ grade 2 No prior severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent filgrastim ( GCSF ) sargramostim ( GMCSF ) Chemotherapy No prior chemotherapy , include estramustine suramin prostate cancer No concurrent chemotherapy Endocrine therapy See Disease Characteristics At least 4 week since prior antiandrogen therapy No concurrent hormonal therapy except steroid adrenal insufficiency , hormone nondiseaserelated condition ( e.g. , insulin diabetes ) , intermittent dexamethasone antiemetic Radiotherapy See Disease Characteristics At least 4 week since prior radiotherapy At least 8 week since prior strontium chloride Sr 89 samarium Sm 153 lexidronam pentasodium No concurrent palliative radiotherapy Surgery See Disease Characteristics At least 4 week since prior surgery recover</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>